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Abstract
Background Gastric signet ring cell carcinoma (GSRC) is a rare but increasingly prevalent tumor histotype whose clinical 
features and natural history are poorly understood, particularly in the USA and minorities.
Aims To examine the occurrence, clinico-demographic characteristics, oncologic features, treatment, and outcomes of GSRC 
in a predominantly minority county hospital setting and benchmark them against data from the National Cancer Institute’s 
Surveillance, Epidemiology, and End Results (SEER) program.
Methods We queried biopsy-proven GSRC cases at a Los Angeles County hospital, from 2004 to 2017. Clinical character-
istics, treatment, and survival data were collected and compared to SEER data.
Results We identified 63 patients with GSRC. Compared to SEER, our cohort was significantly younger (52.6 vs. 63.5 years, 
p < 0.01), Hispanic/Latino predominant (81% vs. 20%, p < 0.01), had higher overall stage (86% vs. 69% with stage III/IV, 
p < 0.01), and more frequent node involvement (89% vs. 49%, p < 0.01). Lower tumor stage, Helicobacter pylori positivity, 
and surgical intervention were associated with significantly longer median survival (all p < 0.05), which was similar in our 
study compared to SEER (median 12.6 vs. 9.0 months, p = 0.26).
Conclusions Patients with GSRC within the Los Angeles County population have different clinical characteristics compared 
to what has been reported in SEER. Our cohort was younger, and despite having more advanced disease, did not have shorter 
survival. Further study is needed to better identify protective and risk factors in this population and improve understanding 
of the etiopathogenesis and natural history of this malignancy.
Keywords SEER · Minority health · Hispanic population · Helicobacter pylori · Los Angeles County
Introduction
Gastric cancer is the sixth most common malignancy world-
wide, with approximately 1.2 million new cases diagnosed 
in 2016 [1]. Despite its overall declining incidence in recent 
years, gastric cancer is still the second leading cause of 
cancer-related death worldwide [1, 2]. Furthermore, the 
incidence of a specific histotype of gastric cancer, signet 
ring cell carcinoma (SRC), has been increasing in recent 
years [3]. Indeed, data from the National Cancer Institute’s 
Surveillance, Epidemiology, and End Results (SEER) pro-
gram demonstrate a tenfold increase in the incidence of 
SRC between 1973 and 2000 [3, 4]. Newer SEER data have 
shown that even in light of national cancer detection and pre-
vention efforts, the incidence of SRC has not decreased [5].
Despite these troubling statistics, data from the USA 
regarding GSRC are particularly scarce, in part due to SRC 
being an uncommon malignancy. According to the World 
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Health Organization (WHO) classification, GSRC is a his-
tological type of epithelial carcinoma based on more than 
50% of the tumor containing intracytoplasmic mucin. This 
globoid, optically clear glycoprotein pushes the cells’ nuclei 
against the cell membrane, creating what has been classi-
cally described as a “signet ring” appearance [6]. Compared 
to other gastric cancer types, it has been reported to have a 
female predominance, younger age at diagnosis, and late 
presentation, making treatment particularly challenging [7, 
8]. Although there have been studies of the clinicopatho-
logical features and prognosis of GSRC, results have been 
inconsistent, with some reports showing SRC to have a bet-
ter prognosis than other gastric carcinomas [9], some show-
ing no significant difference [10, 11], and others reporting a 
poorer prognosis [8].
At our institution, a predominantly minority county hos-
pital in Los Angeles County, it was independently observed 
by both the Department of Pathology and Department of 
Medicine that the number of GSRC cases seemed surpris-
ingly large and the presentation commonly in young patients. 
We therefore aimed to examine the occurrence, features, and 
outcomes of GSRC in this unique population and bench-
marked these characteristics against SEER data.
Methods
This study was approved by the Institutional Review Board 
of Olive View-UCLA Medical Center.
Patients and Setting
We retrospectively identified all patients greater than 
18 years of age with a biopsy-proven diagnosis of GSRC 
at Olive View-UCLA Medical Center between the years of 
2004 and 2017. Olive View-UCLA Medical Center is a 377-
bed academic hospital which serves a population of over 
2 million people within a catchment area of nearly 1000 
square miles and is operated by the Los Angeles County 
Department of Health Services, the second largest municipal 
health care system in the USA [12]. Approximately 65% of 
the population served by the institution identify as Hispanic/
Latino (hereinafter “Latino”), and over 50% speak a primary 
language other than English [13]. Sixty percent of patients 
are foreign born, of which 20% were born in Mexico, 7% 
in the Philippines, 6% in El Salvador, 4% in Guatemala, 
and another 5% from other Central and South American 
countries.
In order to compare the characteristics and outcomes of 
patients in this study with that of other cohorts, we abstracted 
data from the National Cancer Institute’s SEER program. 
The SEER database represents the most comprehensive can-
cer registry in the USA, representing approximately 27.8% 
of the US population [14]. We selected patients with GSRC 
using the International Classification of Diseases for Oncol-
ogy, 3rd edition (ICD-O-3) code 8490 and filtering only for 
cases of gastric primary. SEER data that were abstracted 
included gender, race, tumor location, T stage, N stage, over-
all cancer stage, tumor differentiation, and survival time.
Study Variables and Outcomes
Comprehensive demographic, clinical, endoscopic, histo-
pathologic, imaging, and oncologic data were abstracted 
from the medical record using a standardized data collec-
tion form, including: sex, age at diagnosis, race, tumor size, 
tumor location, TMN stage, differentiation, lymph node 
involvement, type of surgery, neoadjuvant and adjuvant 
chemotherapy, Helicobacter pylori (H. pylori) infection 
status, and time to death or hospice.
The primary outcome was survival, defined as time to 
either death or hospice. Covariates included patient charac-
teristics (age, gender, race), presenting tumor features (stage, 
size, tumor location, tumor differentiation), and H. pylori 
status. We compared these features to SEER data when avail-
able, both overall as well as within the subgroup of Latino 
patients. Age at diagnosis was determined by subtracting the 
year of birth from the year of diagnosis. Similarly, time to 
death or hospice was determined by subtracting the date of 
death or date of hospice initiation from the date of diagnosis. 
Pathological stage was classified according to the Ameri-
can Joint Committee on Cancer (AJCC) staging manual, 
7th edition [15]. Helicobacter pylori status was determined 
by reviewing histopathology reports (most often confirmed 
by Warthin-Starry silver stain), serum H. pylori IgG anti-
body, or stool H. pylori antigen testing results. Patients were 
categorized as H. pylori positive if any of the three testing 
methods were positive and H. pylori negative if all H. pylori 
tests that were performed were negative. Patients without 
documented H. pylori testing were categorized as unknown 
status.
Statistical Analysis
Demographic and clinical characteristics were examined 
using descriptive statistics. Means were compared using 
independent t-tests. Variables which were not normally 
distributed (or that otherwise did not satisfy assumptions 
for parametric tests) were summarized and compared using 
nonparametric tests. Overall and subgroup (sex, age, tumor 
size, tumor stage, H. pylori status) survival curves were 
generated using the Kaplan–Meier method and then com-
pared with the log-rank test. Time to hospice or death (by 
any cause) was used as a proxy for approximating survival. 
All study data were analyzed using IBM SPSS Statistics 23 
(SPSS, Inc., Chicago, IL). SEER data were analyzed using 
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the SEER*Stat software (version 8.3.5, National Cancer 




A total of 63 patients with a diagnosis of GSRC during the 
study period were identified, yielding an overall estimated 
annual incidence of approximately 6.22 per 100,000 persons. 
Of these 63 patients, 81.0% were Latino, 7.9% White, 6.3% 
Other, and 4.8% Asian/Pacific Islander (Table 1). Cases of 
GSRC had a female predominance (57.1%). The mean age 
at diagnosis was 52.6 (standard deviation [SD] 11.9) years. 
Of the 41 patients (65.1%) in our sample who had H. pylori 
testing data, recent or ongoing H. pylori infection was pre-
sent in 75.6% of patients, of which 38.7% were diagnosed 
by serum antibody, 48.4% by histopathology, 6.5% by stool 
antigen, and 6.5% by a combination of serum antibody and 
histopathology. Median follow-up was 8.3 months (inter-
quartile range 2.2–18.1 months). The most common pre-
senting symptoms were abdominal pain, nausea, vomiting, 
and/or dyspepsia. Four patients were asymptomatic at initial 
presentation; of these four, two underwent endoscopy for 
evaluation of iron deficiency anemia, one for esophageal 
varix screening, and one for an incidental finding on radio-
graphic imaging.
Tumor Presentation
Mean tumor size was 6.8 (SD 5.1) cm (Table 2). Approxi-
mately 8.9% of cases were located at the gastroesophageal 
junction, 2.2% in the gastric fundus, 37.8% in the body, 
24.4% in the antrum, and 36.7% in multiple locations or 
diffusely. Over 75% of patients presented with tumor stages 
T3 or T4, and nearly 90% presented with lymph node metas-
tases. Eighty-six percent of patients presented with cancer 
stage III or IV, and approximately 87% had poorly differenti-
ated (G3) or undifferentiated (G4) histology.
Oncologic Treatment
Sixty-two percent of patients underwent either subtotal or 
total gastrectomy (Table 3). Approximately 10% had neo-
adjuvant chemotherapy consisting of capecitabine and an 
alkylating antineoplastic agent (either cisplatin or oxalipl-
atin), ± epirubicin. Seventy-six percent of patients received 
adjuvant chemotherapy (most frequently with 5-fluorouracil 
and radiotherapy via the Macdonald protocol) with either 
palliative or curative intent.
Table 1  Clinical and 
demographic characteristics of 
patients with gastric signet ring 
cell carcinoma
*Refers to the number of cases with available data pertaining to this variable
Variables All Hispanic
n (%) SEER n (%) p n (%) SEER n (%) p
N 63 22,724 51 4620
Female 36 (57.1) 10,924 (48.1) 0.150 32 (62.7) 2370 (51.3) 0.104
Mean age at diagnosis (in years) 52.6 ± 11.9 63.5 ± 15.2 0.003 52.6 ± 12.1 57.0 ± 15.4 0.008
Ethnicity
 Latino/Hispanic 51 (81.0) 4620 (20.3) 51 (100.0) 4620 (100.0)
 White 5 (7.9) 11,747 (51.7) 0 (0.0) 0 (0.0)
 Asian/Pacific Islander 3 (4.8) 3388 (14.9) 0 (0.0) 0 (0.0)
 Black 0 (0) 2717 (12.0) 0 (0.0) 0 (0.0)
 Other 4 (6.3) 252 (1.1) 0 (0.0) 0 (0.0)
H. pylori 41* Not available 31* Not available
 Positive 31 (75.6) 26 (83.9)
  Serum antibody only 12 (38.7) 11 (42.3)
  Histopathology only 15 (48.4) 12 (46.2)
  Stool antigen only 2 (6.5) 2 (7.7)
  Combination of ≥ 2 methods 2 (6.5) 1 (3.8)
 Negative 10 (24.4) 5 (16.1)
Presenting symptom 63* Not available 63* Not available
 Abdominal pain, nausea, vom-
iting, and/or dyspepsia
58 (92.1) 47 (92.1)
 Asymptomatic 4 (6.3) 3 (5.9)
 Unknown 1 (1.6) 1 (2.0)
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Table 2  GSRC tumor 
characteristics
GE gastroesophageal, GSRC gastric signet ring cell carcinoma, NOS not otherwise specified
*Refers to the number of cases with available data pertaining to this variable
a Excludes tumors from post-adjuvant chemotherapy
b Tumors without specification of location not included
c Includes tumors found on lesser and greater curvature
d Comparison of low T stage (T0, T1, T2) versus high T stage (T3, T4)
e Comparison of no lymph node involvement (N0) versus lymph node involvement (N1, N2, N3)
f Comparison of low overall stage (0, I, II) versus high overall stage (III, IV)
g Comparison of low tumor grade (well differentiated, moderately differentiated) versus high tumor grade 
(poorly differentiated, undifferentiated)
Variables All Hispanic
n (%) SEER n (%) p n (%) SEER n (%) p
N 63 22,724 51 4620
Tumor size 33* Not available 27* Not available
 Mean tumor size (cm)a 6.8 ± 5.1 7.2 ± 5.4
 Median tumor size (cm) 5.5 5.5
Tumor  locationb 45* 18,060* 36* 3635*
 GE junction 4 (8.9) 3665 (20.3) 3 (8.3) 394 (10.8)
 Fundus 1 (2.2) 698 (3.9) 1 (2.8) 137 (3.8)
 Bodyc 17 (37.8) 5486 (30.4) 15 (41.7) 1305 (35.9)
 Antrum 11 (24.4) 5603 (31.0) 7 (19.4) 1158 (31.9)
 Multisite 12 (26.7) 2608 (14.4) 10 (27.8) 641 (17.6)
Depth of invasion 30* 4739* 0.075d 25* 1169* 0.101d
 T0 0 (0.0) 20 (0.4) 0 (0.0) 4 (0.3)
 T1 1 (3.3) 1314 (27.7) 1 (4.0) 288 (24.6)
 T2 6 (20.0) 525 (11.1) 4 (16.0) 127 (10.9)
 T3 14 (46.7) 1366 (28.8) 12 (48.0) 317 (27.1)
 T4 9 (30.0) 1514 (32.0) 8 (32.0) 433 (37.0)
Lymph node metastasis 27* 5538* < 0.001e 23* 1413* < 0.001e
 N0 4 (14.8) 2852 (51.5) 3 (13.0) 720 (51.0)
 N1 4 (14.8) 1401 (25.3) 3 (13.0) 368 (26.0)
 N2 12 (44.4) 516 (9.3) 11 (47.8) 128 (9.1)
 N3 7 (30.0) 769 (13.9) 6 (26.1) 197 (13.9)
Stage 50* 5752* 0.009f 43* 1509* 0.032f
 0 0 (0.0) 4 (0.0) 0 (0.0) 0 (0.0)
 Ia 0 (0.0) 694 (12.1) 0 (0.0) 148 (9.8)
 Ib 3 (6.0) 317 (5.5) 1 (2.3) 83 (5.5)
 IIa 1 (2.0) 332 (5.8) 1 (2.3) 74 (4.9)
 IIb 3 (6.0) 450 (7.8) 3 (7.0) 90 (6.0)
 IIIa 8 (16.0) 420 (7.3) 7 (16.3) 93 (6.2)
 IIIb 5 (10.0) 423 (7.4) 4 (9.3) 105 (7.0)
 IIIc 3 (6.0) 461 (8.0) 3 (7.0) 92 (6.1)
 III NOS 0 (0.0) 19 (0.3) 0 (0.0) 2 (0.1)
 IV 27 (54.0) 2632 (45.8) 24 (55.8) 822 (54.5)
Differentiation (n = 38) 40* 17,766* 0.002g 32* 3740* < 0.001g
 Well differentiated 0 (0.0) 82 (0.5) 0 (0.0) 8 (0.2)
 Moderately differentiated 5 (12.5) 545 (3.1) 5 (15.6) 84 (2.2)
 Poorly differentiated 32 (80.0) 16,453 (92.6) 26 (81.2) 3552 (95.0)
 Undifferentiated 3 (7.5) 686 (3.9) 1 (3.1) 96 (2.6)
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Survival Outcomes
The median time between date of diagnosis and date of death 
or hospice initiation was 12.6 months, and 5-year survival 
was 14.3% (Table 3 and Figs. 1 and 2). Within 2 years of 
diagnosis, 88% of patients were either deceased or in hos-
pice care. Median survival in males and females did not 
differ (12.9 vs. 12.6 months, p = 0.406), and there was no 
significant difference in survival between patients who 
were younger than 52 (the median age of patients in this 
study) and older than 52 years of age at diagnosis (15.8 vs. 
11.4 months, p = 0.291). Similarly, there was no significant 
difference in median survival between patients with tumors 
smaller than 5.5 cm (the median tumor size in this study) 
and larger than 5.5 cm (20.3 vs. 12.9 months, p = 0.171), 
though there appeared to be a clinically significant trend 
toward shorter survival with larger tumors. Higher overall 
cancer stage (stage IV vs. stage I–III) was associated with 
shorter survival (4.2 months vs. 20.4 months, p = 0.001). 
Patients with recent or active H. pylori infection were found 
to have longer survival than patients who tested negative 
for H. pylori (17.9 vs. 5.6 months, p = 0.017). Patients who 
underwent surgical intervention had longer survival than 
patients who did not undergo surgery (20.4 vs. 3.3 months, 
p < 0.001). Survival did not appear to be associated with 
whether or not patients received chemotherapy (13.0 vs. 
17.9 months, p = 0.618). These predictors of survival are 
shown in Fig. 2.
Comparisons to SEER Data
Compared to SEER data, the mean age at GSRC diagno-
sis was younger in our study cohort, with the average age 
of diagnosis being 10 years earlier (52.6 vs. 63.5 years, 
p < 0.01). Our study cohort also had a higher percentage 
of females, with 57.1% of patients with a new diagnosis of 
GSRC being female compared to 45% in SEER (p = 0.15). 
A higher percentage of patients presented with advanced 
cancer staging; 86% of patients presented with stage III 
or IV disease compared with 68.8% in SEER (p < 0.01). 
Lymph node involvement was also higher in this population 
(89.2% vs. 48.5%, p < 0.01). However, a lower percentage of 
patients had poorly differentiated or undifferentiated tumors 
(87.5% vs. 95.6%, p < 0.01). Despite more frequent advanced 
staging and lymph node involvement, patients in our study 
appeared to have similar survival to those in SEER (12.6 vs. 
9.0 months, p = 0.26).
Further analysis comparing only Latino patients in our 
cohort to Latino patients in SEER revealed similar find-
ings: average age of diagnosis was still younger in our 
cohort (though the age gap was smaller, 52.6 vs. 57.0 years, 
p = 0.01), the proportion of females with GSRC was higher 
(62.7% vs. 51.3%, p = 0.10), the percentage of patients with 
advanced cancer staging (stage III or IV) and lymph node 
involvement was higher (80% vs. 64.1%, p = 0.03 and 73.9% 
vs. 23.0%, p < 0.01, respectively), the percentage of patients 
with poorly differentiated of undifferentiated tumors was 
Table 3  Outcomes of patients with GSRC
*Refers to the number of cases with available data pertaining to this variable
Variables All Hispanic
n (%) SEER n (%) p n (%) SEER n (%) p
Surgery 56* Not available 48* Not available
 Gastrectomy (subtotal) 22 (39.3) 16 (33.3)
 Gastrectomy (total) 13 (23.2) 12 (25.0)
 No surgery 21 (37.5) 20 (41.7)
Neoadjuvant chemotherapy 51* Not available 43* Not available
 Yes 5 (9.8) 5 (11.6)
 No 46 (90.2) 38 (88.4)
Chemotherapy 51* Not available 43* Not available
 Yes (palliative and curative) 39 (76.5) 33 (76.7)
 No 12 (23.5) 10 (23.3)
Survival 61* 20,717* 51* 4409*
 Median survival (months) 12.6 9 0.26 12.2 10.0 0.49
 3 months 44/55 (80.0) 15,118/20,278 (74.6) 38/48 (79.2) 3232/4239 (76.2)
 6 months 33/53 (62.3) 12,080/20,033 (60.3) 27/46 (58.7) 2497/4139 (60.3)
 12 months 27/51 (52.9) 8201/19,695 (41.6) 22/45 (48.9) 1630/4044 (40.3)
 24 months 10/45 (22.2) 4878/19,278 (25.3) 9/42 (21.4) 955/3942 (24.2)
 60 months 6/42 (14.3) 2282/18,618 (12.3) 5/39 (12.8) 413/3754 (11.0)
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Fig. 1  Kaplan–Meier survival curves of patients with gastric sig-
net ring cell carcinoma. Kaplan–Meier survival curves comparing 
months of survival in gastric signet ring cell carcinoma (GSRC) are 
shown for a all patients, b by gender (p = 0.406), c by age at diagnosis 
(p = 0.291), d by tumor size (p = 0.171), e by cancer stage (p = 0.004), 
f by H. pylori infection status (p = 0.017), g by surgical intervention 
(p < 0.001), and h by chemotherapy (p = 0.618). All comparisons per-
formed by log-rank tests
Digestive Diseases and Sciences 
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lower (84.3% vs. 97.6%), and survival was similar (12.2 vs. 
10.0 months, p = 0.49).
Discussion
GSRC is a rare but highly lethal malignancy whose inci-
dence, in contrast to gastric cancer overall, does not appear 
to be decreasing in the USA. In this study, we aimed to 
examine and better understand the clinical epidemiology 
of GSRC in the USA and specifically the predominantly 
minority patient population of Los Angeles County. Our 
main findings are that patients with GSRC in our cohort, 
compared to SEER, had: (1) younger age at diagnosis, (2) 
more advanced staging and lymph node involvement, and 
(3) similar survival times. Furthermore, we estimated the 
incidence of GSRC in our patient population to be 6.22 per 
100,000 persons, higher than what has been reported in 
SEER, 1.27 per 100,000 persons [16]. However, this is likely 
an overestimate due to the fact that this study was performed 
at a tertiary referral center.
We believe that ethnoracial (and possibly geographical 
and environmental) factors may play a role in the differ-
ences in mean age at GSRC diagnosis observed between our 
Los Angeles County-based cohort and SEER. Indeed, when 
including only Latino patients from the SEER database, we 
found the average age of diagnosis to be 57 years, which is 
more similar to our cohort (52.6 years) and younger than 
SEER patients overall (63.5 years). This suggests that Latino 
patients may represent a high-risk group for developing 
GSRC (i.e., at a younger age) [17]. In addition, the younger 
age of diagnosis in Latino patients appears to be similar to 
and in some cases even earlier than other populations tra-
ditionally considered to be high-risk [18–20]. Cancer regis-
tries from Latin American countries are not available at this 
time to determine if the natural history of GSRC in Latino 
patients is similar internationally compared to the USA.
Our finding that 57.1% of patients with a new diagnoses 
of GSRC were female is higher than both SEER data as well 
as prior studies of patients with GSRC, though was not sig-
nificant at the 0.05 level [10, 11, 18–20]. While it is unclear 
why the proportion of females was higher in this study, sev-
eral other studies have found that a higher percentage of 
GSRC patients are female when compared with non-GSRC 
patients. It has been hypothesized that SRC histology may 
be influenced by female sex hormones, as estrogen recep-
tors have frequently been found to be expressed in poorly 
differentiated gastric cancer, thus suggesting a relationship 
between hormone environment and SRC [21].
A higher percentage of patients presented with advanced 
cancer staging and lymph node involvement. Interestingly, 
the presentation of GSRC has been observed to differ 
between studies from the West compared to the East; for 
example, US studies have reported GSRC to be associated 
with advanced staging upon presentation, while many Asian 
studies suggest that GSRC is diagnosed at earlier stages [11, 
18, 19, 22]. One potential explanation for this difference is 
variation in preventative cancer screening practices through-
out the world. Asian countries such as Korea and Japan have 
programs for and high participation rates in gastric cancer 
screening [23, 24], which would likely contribute to can-
cers being detected in earlier stages. Conversely, in Western 
Fig. 2  Demographic and 
clinical predictors of survival. 
Shown in the plotted data is 
median survival as a function of 
various dichotomized demo-
graphic and clinical variables. 
The following variables were 
associated with shortened sur-
vival (i.e. shorter time to death 
or hospice), as indicated by an 
asterisk: advanced TNM stage 
(p = 0.001), H. pylori negativ-
ity (p = 0.017), and no surgery 
(p < 0.001). Whiskers indicate 
95% confidence intervals
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countries, diagnostic testing is often performed only after 
symptom onset. In the present study, patients presented with 
even more advanced presentations than has been previously 
reported in Western studies, potentially in part due to delays 
in and difficulties with access to health care in this largely 
uninsured population. Routine screening for gastric cancer 
in asymptomatic patients is not currently performed at our 
hospital.
Even with more advanced staging and lymph node 
involvement, survival appeared to be similar in this popula-
tion compared to SEER data. In SEER, the median survival 
was 9.0 months. Although we were not able to calculate true 
median survival due to limited survival data, by including 
time until hospice, we found the mean time to death or ini-
tiation of hospice to be 12.6 months, indicating the possible 
existence of protective factors in this population. From their 
analysis of SEER data from 2004 to 2007, Taghavi et al. pre-
viously indicated that age of diagnosis, Hispanic ethnicity, 
size and extent of the tumor (T), nodal involvement (N), his-
tologic grade, and overall stage are associated with increased 
mortality [11]. In our study, though the majority of patients 
were Latino and had relatively high overall stage and lymph 
node involvement, the average age of diagnosis was younger, 
and the percentage of high grade tumors (poorly differenti-
ated and undifferentiated combined) was lower (86.8% vs. 
96.5%), thus ostensibly contributing to better survival out-
comes [17].
In survival analyses, we found no significant difference 
in survival based on gender, age, tumor size, and treatment 
with chemotherapy. However, as expected, longer survival 
times were observed for patients with lower tumor stages. 
We also found improved survival with surgery (gastrectomy) 
versus no surgery, but the no surgery group was expectedly 
biased toward more advanced tumor staging (all had T4 dis-
ease), as it was the patients with metastatic disease who were 
usually not surgical candidates. Lastly, we found improved 
survival with H. pylori positivity. Previous studies of H. 
pylori and gastric cancer have found that most patients with 
gastric cancer are H. pylori-positive, with reported seroposi-
tivity rates varying from 80 to 100% [25, 26]. For the small 
percentage of patients with H. pylori-negative gastric cancer, 
the most common subtype is SRC [27]. However, the role 
of H. pylori in GSRC is unclear, as there have been very 
few studies on this subject. Horiuchi et al. found that the 
proliferative ability of cancer was higher in GSRC patients 
who were H. pylori-positive than those who were H. pylori 
negative, suggesting that H. pylori-positive gastric cancers 
of the SRC subtype progress more rapidly [27]. Although 
our results do not seem consistent with this previous finding, 
a direct comparison cannot be made, as survival was not ana-
lyzed in the aforementioned study. One possible explanation 
for our findings is that H. pylori-positive patients, by having 
earlier symptoms, may undergo earlier testing, resulting in 
earlier diagnosis and treatment. We believe more studies are 
needed to better evaluate and understand the impact of H. 
pylori on GSRC outcomes.
Our study has several limitations. Because the incidence 
of GSRC is low and our sample size is small, we have lim-
ited ability to generalize our findings to other settings. Con-
clusions regarding the role of risks factors such as H. pylori 
positivity are also limited by the sample size and the avail-
ability of H. pylori infection data in only approximately two-
thirds of patients. A related concern is the lack of mortality 
data for some patients; to approximate survival, we created 
a composite of time to death and time to hospice initiation, 
which may systematically underestimate mean survival. In 
addition, this study could not assess the impact of several 
key demographic and socioeconomic variables, including 
family income level, education level, geographic location, 
duration of residence in the USA, and country of origin, on 
the development, features, and outcomes of GSRC.
Despite the aforementioned limitations, our study has 
multiple strengths. Although the sample size is small, it rep-
resents one of the largest well-characterized GSRC cohorts 
in the USA and the only cohort based in a county hospital 
setting. Our study also highlights important differences in 
the presentation and prognosis of this malignancy in minor-
ity populations and suggests areas in need of future research.
Conclusions
In this first USA-based study to examine the occurrence, 
features, and outcomes of GSRC at a predominately minor-
ity Los Angeles County medical center, we found the mean 
age at GSRC diagnosis was younger and overall stage was 
more advanced than that which has been reported in SEER 
data. Despite presenting with higher overall stage and more 
lymph node involvement, median survival was similar, sug-
gesting possible protective factors in this population. Addi-
tional studies are needed and planned to better understand 
the epidemiology, pathogenesis, natural history, and treat-
ment outcomes of GSRC and evaluate whether there may 
be a need for tailored screening programs in this unique and 
traditionally understudied population.
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